Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Sales

Fulcrum Therapeutics (FULC) Operating Margin (2020 - 2024)

Fulcrum Therapeutics (FULC) has disclosed Operating Margin for 4 consecutive years, with 3615.28% as the latest value for Q3 2023.

  • On a quarterly basis, Operating Margin changed N/A to 3615.28% in Q3 2023 year-over-year; TTM through Mar 2025 was 121.38%, a 463754.0% increase, with the full-year FY2024 number at 27.37%, up 391787.0% from a year prior.
  • Operating Margin was 3615.28% for Q3 2023 at Fulcrum Therapeutics, up from 9471.19% in the prior quarter.
  • In the past five years, Operating Margin ranged from a high of 355.88% in Q1 2021 to a low of 9471.19% in Q1 2023.
  • A 4-year average of 1863.12% and a median of 899.6% in 2022 define the central range for Operating Margin.
  • Peak YoY movement for Operating Margin: surged 215026bps in 2021, then tumbled -846818bps in 2023.
  • Fulcrum Therapeutics' Operating Margin stood at 420.99% in 2020, then dropped by -11bps to 465.78% in 2021, then crashed by -291bps to 1819.08% in 2022, then tumbled by -99bps to 3615.28% in 2023.
  • Per Business Quant, the three most recent readings for FULC's Operating Margin are 3615.28% (Q3 2023), 9471.19% (Q1 2023), and 1819.08% (Q2 2022).